A Roundup of This Week's #CureFacts

The Food and Drug Administration approved Breyanzi for patients with pretreated, relapsed or refractory follicular lymphoma.

Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.

As a cancer survivor, I’m pleading for more research on cancer related fatigue.

In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, and how to manage them.

This poem is a reflection of some of my thoughts and feelings when my wife received a diagnosis of triple-negative breast cancer.

A metastatic breast cancer diagnosis can come as “a shock,” but experts spoke with CURE® about ways patients can navigate their experiences and treatments.